Published in Pol Arch Med Wewn on April 03, 2009
Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer (2013) 1.00
Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer. PLoS One (2015) 0.93
Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma. J Transl Med (2012) 0.93
CYFRA 21-1 in urine: a diagnostic marker for endometriosis? Int J Womens Health (2015) 0.77
Fibroblast phenotypes in different lung diseases. J Cardiothorac Surg (2014) 0.76
Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis. Oncotarget (2017) 0.75
The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. BMC Cancer (2017) 0.75
Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study. J Thorac Dis (2016) 0.75
EMT influences the expression of CK19 in pleural effusion-derived lung cancer cells and their invasion and metastasis. Oncol Lett (2016) 0.75
Club cell protein 16 and cytokeratin fragment 21-1 as early predictors of pulmonary complications in polytraumatized patients with severe chest trauma. PLoS One (2017) 0.75
The value of circulating CYFRA21-1 expression in patients with nasopharyngeal carcinoma: a study of 529 subjects. Int J Clin Oncol (2016) 0.75
Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors. Iran J Otorhinolaryngol (2017) 0.75
CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer. Hum Immunol (2011) 0.91
[Alveolar proteinosis after professional exposure to cotton and linen dust, successfully treated with whole lung lavage--a case report]. Pneumonol Alergol Pol (2004) 0.87
Fucosylation of serum glycoproteins in lung cancer patients. Clin Chem Lab Med (2005) 0.87
Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res (2011) 0.86
Does the KIR2DS5 gene protect from some human diseases? PLoS One (2010) 0.86
Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients. Exp Mol Pathol (2012) 0.85
Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer. Anticancer Res (2011) 0.85
Expression of metallothionein-III in patients with non-small cell lung cancer. Anticancer Res (2013) 0.84
Apoptotic regulators: P53 and survivin expression in non-small cell lung cancer. Cancer Genomics Proteomics (2010) 0.84
KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Hum Immunol (2012) 0.84
Comparison of haptoglobin and alpha₁-acid glycoprotein glycosylation in the sera of small cell and non-small cell lung cancer patients. Postepy Hig Med Dosw (Online) (2013) 0.83
Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer. Oncol Rep (2009) 0.82
[Combined pulmonary fibrosis and emphysema - case report and literature review]. Pneumonol Alergol Pol (2009) 0.82
Laryngeal tuberculosis. Lancet Infect Dis (2004) 0.82
Role of lymphangiogenesis in lung cancer. Folia Histochem Cytobiol (2009) 0.81
[The prognostic value of cytokeratin 19 expression in non-small cell lung cancer]. Pneumonol Alergol Pol (2007) 0.80
[Leptin serum levels in cachectic and non-cachectic lung cancer patients]. Pneumonol Alergol Pol (2009) 0.80
Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo (2006) 0.80
[Comparative evaluation of two health-related quality of life questionnaires in patients with sleep apnea]. Wiad Lek (2004) 0.79
Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives. Bioorg Med Chem Lett (2004) 0.79
Stilbene analogs as inducers of apolipoprotein-I transcription. Eur J Med Chem (2010) 0.78
Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA. In Vivo (2009) 0.78
The evaluation of body composition, adiponectin, C-reactive protein and cholesterol levels in patients with obstructive sleep apnea syndrome. Adv Clin Exp Med (2014) 0.78
[Expression of p53, bcl-2 and nm23 proteins in squamous cell lung cancer]. Pneumonol Alergol Pol (2009) 0.78
[Serum chitotriosidase activity as a biomarker of pulmonary sarcoidosis]. Pol Merkur Lekarski (2011) 0.77
[The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report]. Pol Merkur Lekarski (2010) 0.77
[The epidemiology of lung cancer]. Pneumonol Alergol Pol (2007) 0.77
Presence of high-molecular-weight forms and domain alterations of fibronectin in pleural effusion of patients with lung cancer. Clin Biochem (2009) 0.77
[Tuberculosis after renal transplantation]. Pneumonol Alergol Pol (2009) 0.77
[The most common infections of lung allografts]. Pneumonol Alergol Pol (2009) 0.77
[Suppression of chronic nocturnal cough during continuous positive airway pressure (CPAP) treatment in a patient with asthma and obstructive sleep apnea syndrome]. Pneumonol Alergol Pol (2011) 0.77
[Assessment of sociodemographic and nutritional status of lung cancer patients]. Rocz Panstw Zakl Hig (2011) 0.77
[Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report)]. Pol Merkur Lekarski (2009) 0.76
Serum levels of apoptosis-related markers (sFasL, TNF-a, p53 and bcl-2) in COPD patients. Pneumonol Alergol Pol (2015) 0.76
[Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease]. Pol Merkur Lekarski (2011) 0.76
[Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy]. Pol Merkur Lekarski (2002) 0.75
[Nutritional knowlegde and lifestyle of obese patients with diagnosed obturative sleep apnea]. Rocz Panstw Zakl Hig (2010) 0.75
Hypoxemia during bilevel positive airway pressure treatment in patients with obstructive sleep apnea syndrome and chronic respiratory insufficiency. Adv Exp Med Biol (2013) 0.75
[VEGF in the cancer anorexia-cachexia syndrome in patients with lung cancer]. Pneumonol Alergol Pol (2006) 0.75
[The effect of inhaled low molecular weight heparin on cell composition in bronchoalveolar lavage fluid and serum levels of soluble receptor IL-2 in bronchial asthma patients]. Pol Merkur Lekarski (2002) 0.75
[Cathepsin B activity and concentration of elastase and alpha-1 proteinase inhibitor complex in non-small-cell lung cancer: 2 year follow-up study]. Pol Merkur Lekarski (2003) 0.75
[Anticancer chemotherapy containing cisplatin in patients with lung cancer and kidney function]. Pol Arch Med Wewn (2002) 0.75
The total synthesis of racemic teucvin and 12-epi-teucvin. Angew Chem Int Ed Engl (2003) 0.75
[Coexistence of obstructive sleep apnea syndrome and chronic obstructive pulmonary disease]. Pneumonol Alergol Pol (2011) 0.75
[Changes in the percentage of activated lymphocytes in bronchoalveolar lavage fluid in patients with clinical improvement of sarcoidosis]. Wiad Lek (2006) 0.75
[Diagnosis and treatment of tobacco dependence]. Pneumonol Alergol Pol (2005) 0.75
[Increase of skin reactivity to histamine in patients after lung cancer surgery]. Pneumonol Alergol Pol (2002) 0.75
[Chronic obstructive pulmonary disease and cardiovascular diseases]. Pneumonol Alergol Pol (2010) 0.75
[Application of metabolomic in COPD diagnosing]. Pol Merkur Lekarski (2012) 0.75
[Wegener's granulomatosis--a disease of many faces]. Pneumonol Alergol Pol (2002) 0.75
[Elastase and alpha-1 proteinase inhibitor complex in broncho-alveolar lavage fluid in patients with bronchial asthma and sarcoidosis]. Pol Merkur Lekarski (2003) 0.75
Skin reactivity to histamine and expression of histamine receptors mRNA in lymphocytes of healthy subjects and non-small-cell lung cancer patients before and after surgery. Lung Cancer (2004) 0.75
[Phagocytosis and chemiluminescence of neutrophils in patients with pulmonary tuberculosis]. Pol Merkur Lekarski (2003) 0.75
[Treatment of nicotine dependence based on bupropion SR and educational support--one year observation and analysis of the reasons of relapses]. Pneumonol Alergol Pol (2004) 0.75
[A case of kappa L-chain primary nodular lung amyloidosis]. Pol Merkur Lekarski (2008) 0.75
[Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group]. Pneumonol Alergol Pol (2007) 0.75
Pulmonary function impairment in patients undergoing allogeneic hematopoietic cell transplantation. Adv Exp Med Biol (2013) 0.75
[Neurosarcoidosis--case report]. Pol Merkur Lekarski (2014) 0.75
[Beta-blockers usage in cardio-vascular diseases co-existing with COPD]. Pol Merkur Lekarski (2012) 0.75
[Quality of life outcomes of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD)]. Wiad Lek (2007) 0.75
[The incidence and pathogenesis of cancer anorexia-cachexia syndrome in lung cancer]. Pneumonol Alergol Pol (2008) 0.75
[Pulmonary hypertension and pulmonary embolism in chronic obstructive pulmonary disease]. Pol Merkur Lekarski (2009) 0.75
[Smoking cessation program based on pharmacological support (bupropion SR). Our own experience]. Pneumonol Alergol Pol (2003) 0.75
[Chronic obstructive pulmonary disease exacerbation--effects on quality of life]. Pol Arch Med Wewn (2005) 0.75
[Dietetic aspects of giving up smoking]. Wiad Lek (2010) 0.75
[Quality of life in patients with obstructive sleep apnea]. Pol Merkur Lekarski (2004) 0.75
[Serum and bronchoalveolar lavage fluid neopterin levels in patients with bronchial asthma]. Pol Merkur Lekarski (2003) 0.75
[The cyclin A, B1, D1 and E expression in advanced non-small cell lung cancer--stages IIIB-IV (preliminary report)]. Pol Merkur Lekarski (2011) 0.75
[Serum levels analysis of TGF-Beta and VEGF in patients with cancer anorexia-cachexia syndrome in lung cancer]. Wiad Lek (2007) 0.75